

Table 2. Endpoint analysis

	Prasugrel group (n=250)	Clopidogrel group (n=250)	P value
Safety endpoints			
PCI-related bleeding			
Hemoglobin reduction: g/dl	1.14±1.07	1.01±0.99	0.266
Hemoglobin reduction ≥3.0 g/dl: n (%)	13 (5.2)	11 (4.4)	0.676
Additional hemostasis: n (%)	29 (11.6)	15 (6.0)	0.027
Hematoma formation: n (%)	16 (6.4)	10 (4.0)	0.243
Blood transfusion: n (%)	5 (2.0)	3 (1.2)	0.475
Composite of PCI-related bleeding: n (%)	56 (22.4)	33 (13.2)	0.007
Non-PCI-related bleeding			
TIMI major bleeding: n (%)	1 (0.4)	1 (0.4)	1.000
TIMI minor bleeding: n (%)	0 (0.0)	0 (0.0)	1.000
Clinically relevant minimal bleeding: n (%)	6 (2.4)	3 (1.2)	0.312
Efficacy endpoint			
All-cause death: n (%)	3 (1.2)	0 (0.0)	0.082
MACE: n (%)	4 (1.6)	8 (3.2)	0.243
MACE + revascularization: (%)	12 (4.0)	26 (10.4)	0.018
Heart failure requiring hospitalization: n (%)	3 (1.2)	5 (2.0)	0.402

PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction, MACE, major adverse cardiovascular events